BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celsion Corporation (CLN) Announces Relocation of Corporate Headquarters to Lawrenceville, New Jersey


7/25/2011 7:21:26 AM

COLUMBIA, MD--(Marketwire - July 25, 2011) - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it expects to relocate its operations and corporate headquarters to Lawrenceville, an area of Lawrence Township in Mercer County, New Jersey. The new headquarters, centrally located between New York City, Philadelphia, Princeton and Trenton, will house the Company's research, clinical development and administrative operations, and accommodate Celsion's anticipated future staffing and facility needs. The Company plans to begin operations in its new headquarters at 997 Lenox Drive by the end of the third quarter.

"With the advance of the HEAT Study, initiation of two Phase 2 studies and greater activity anticipated for preparation of the ThermoDox® NDA, we have outgrown our current location. Celsion's new headquarters sits in proximity to many of the world's top biopharmaceutical companies, research institutions, academic centers and investment sources, providing access to this deep resource pool at a transformative stage in our development," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "This move underscores our commitment to long-term growth and value creation, as we work to build a leading oncology drug development company through the commercialization of ThermoDox® and development of our heat-activated liposomal technology platform."

The Company anticipates no increase in occupancy costs as a result of its relocation. The 66-month lease is contingent upon receiving a Business Employment Incentive Program (BEIP) grant from the New Jersey Economic Development Authority. BEIP grants are available to economically viable expanding or relocating businesses that create jobs in New Jersey.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox®, the Company's lead therapeutic candidate currently in a Phase III study for the treatment of primary liver cancer (the HEAT study), to Yakult-Honsha for the Japanese market and has a partnership agreement with Philips Healthcare to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Investor Contact

David Pitts
Argot Partners
212-600-1902
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES